3,775 results on '"nintedanib"'
Search Results
2. A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
3. A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
4. Myositis Interstitial Lung Disease Nintedanib Trial (MINT)
5. Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (NINTECOR)
6. INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation (INREAL)
7. Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
8. A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
9. INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
10. Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
11. Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
12. Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
13. The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 (ENDCOV-I)
14. Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO)
15. Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
16. Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease (NINTOC-TU)
17. Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
18. Safety and Effectiveness of Nintedanib in Korean Patients
19. A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
20. A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
21. Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
22. Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NintNivo)
23. Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (NINBOST2018)
24. Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
25. A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)
26. Safety of Nintedanib in Real World in China
27. Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
28. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
29. Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability.
30. Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.
31. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
32. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
33. Hypoxia Promotes Invadosome Formation by Lung Fibroblasts.
34. Treatment with low‐dose nintedanib and tacrolimus in patients with progressive fibrosing interstitial lung diseases with anti‐ARS antibody‐positive dermatomyositis.
35. The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis.
36. Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease.
37. Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation.
38. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
39. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy
40. A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
41. Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
42. Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
43. Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
44. A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
45. All-Case Surveillance of Ofev in Patients With IPF in Japan
46. Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
47. Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.
48. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
49. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
50. Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.